Margaret Anderson
Showing 1–9 of 9 transcripts.
- Milken Institute57 min
Health Citizenship: The Nexus of Data, Technology and Research
Margaret Anderson, Stephanie Devaney, Eric Friedman, Joyce Tung, Bernard J. Tyson, Roni Zeiger
This panel introduces the concept of "health citizenship," a strategic shift toward a two-way dialogue between patients and providers that redefines healthcare delivery beyond episodic care. Featuring insights from leaders at Kaiser Permanente, 23andMe, and the All of Us Research Program, the discussion highlights how leveraging diverse data sources, mobile health technologies, and community-based interventions can improve equity and treatment outcomes. The event concludes by emphasizing the necessity of modernizing regulatory frameworks and adopting AI-driven, team-based models to sustain this transition toward proactive, personalized health management.
- Milken Institute1h 12m
Accelerating Medical Research: The Bipartisan Quest for Cures
Margaret Anderson, Bob Hugin, Francis Collins, Mike Milken, Sara Radcliffe, Joe Barton
Hosted by Faster Cures, the 18th Global Conference convened over 160 sessions to address the critical intersection of biomedical innovation and economic stability, featuring strategic insights from Bob Hugin, Mike Milken, and Francis Collins regarding the shrinking purchasing power of NIH funding and China's aggressive bioscience investments. Speakers highlighted the urgent need to revise legislative frameworks, such as the bipartisan 21st Century Cures initiative and dynamic scoring practices, to counter a 23% decline in federal research support that threatens U.S. leadership against global competitors. The event concluded with a unified call to action for sustained advocacy and targeted funding for young scientists to secure future breakthroughs in precision medicine and drug repurposing.
- Milken Institute1h 4m
Precision Medicine: Accelerating Treatments From Potential to Reality
Mike Milken, Margaret Anderson, Pradeep Khosla, Brian Drucker, Betsy Nabel, Sam Hoggud
Distinguished experts including Pradeep Khosla, Brian Drucker, and Sam Hogg convened to discuss the transformation of medicine into a collaborative, data-driven field where precision and artificial intelligence have replaced traditional research silos. Despite significant breakthroughs like the rapid development of Gleevec, panelists warned that underfunding, a lack of trained physician-scientists, and intense global competition threaten U.S. leadership in the bioscience sector. The group concluded that realizing this "golden age of medicine" requires an urgent Apollo-style initiative, multi-sector co-investment, and a cultural shift toward patient partnerships to secure global health preeminence.
- Milken Institute47 min
The 2014 Atlanta Summit - - The Economic Burden of Chronic Disease: Preventing the Preventable
Ross DeVol, Margaret Anderson, Steve Bird, David Heber, Ken Thorpe
Milken Institute's Ross Duvall, Safeway's Steve Bird, UCLA's David Heber, and Emory's Ken Thorpe presented a unified analysis revealing that rising chronic disease prevalence, particularly in diabetes and stroke, is the primary driver of escalating healthcare costs despite controlled medical inflation. The panel highlighted successful private-sector interventions, such as Safeway's biometric wellness programs and social network strategies for obesity, which achieved significant cost reductions by targeting visceral fat and behavioral incentives rather than relying solely on traditional medical treatment. To scale these proven models, the speakers urged policymakers to reframe Medicare reform as a proactive health strategy, overcome Congressional Budget Office scoring constraints, and replace fee-for-service payment structures with value-based incentives that prioritize prevention and early disease management.
- Milken Institute54 min
MI Summit 2013 - London: Funding Medical Breakthroughs, Enriching Society
Ruxandra Draghia-Akli, Gary Nabel, Tim Peakman, Sir Mark Walport, Margaret Anderson
Hosted by Margaret Anderson, a panel of global health leaders including Sir Mark Walport and Gary Nabel convened to address the critical intersection of biomedical innovation and economic prosperity. The discussion highlighted transformative scientific breakthroughs such as universal flu vaccines and T-cell immunotherapy while outlining strategic frameworks like the European Innovative Medicines Initiative to bridge the gap between academic research and commercial application. Participants concluded that overcoming regulatory bottlenecks, scaling genomic sequencing, and fostering public-private collaboration are essential to transforming health data into tangible patient outcomes and national economic growth.
- Milken Institute1h 0m
Bioscience Discoveries That Will Blow Your Mind (updated)
Jack Andraka, David Baltimore, Francis Collins, Tejal Desai, Aydogan Ozcan, Margaret Anderson
Prominent figures including Jack Andraka, Tejal Desai, and NIH Director Francis Collins present breakthroughs in nanotechnology, genomics, and cellular engineering that promise to revolutionize early cancer detection, drug delivery, and precision medicine. While these innovations leverage falling sequencing costs, portable diagnostic devices, and adaptive sensor platforms to bridge the gap between molecular discovery and clinical treatment, panelists express deep concern over a 20% decline in real research funding. The collective discourse underscores an urgent need to redirect resources toward young innovators and high-risk projects to sustain the momentum of this biological renaissance.
- Milken Institute1h 0m
Bioscience Discoveries That Will Blow Your Mind
Jack Andraka, David Baltimore, Francis Collins, Tejal Desai, Aydogan Ozcan, Margaret Anderson
A panel of leading scientists including Jack Andraka, Tejal Desai, David Baltimore, and Francis Collins outlined breakthrough innovations in cancer detection, gene therapy, and nanotechnology while highlighting the transformative potential of open-access data. Despite rapid advancements in genomic sequencing and portable diagnostics, experts warned of a critical decline in U.S. biomedical funding that is discouraging young researchers from pursuing high-risk scientific careers. The discussion concluded with calls to establish special grant programs for early-career innovators and to restore emphasis on curiosity-driven education to sustain future scientific progress.
- Milken Institute1h 3m
Impatient Patients: How Disease Organizations Are Accelerating Research
Margaret Anderson, Lou DiGennaro, Jonathan Simons, Gordon Gunn, Deborah Black, John Walsh
Representatives from Faster Cures and five major disease-focused nonprofits outlined how venture philanthropy and patient-led activism accelerate cures by de-risking early-stage research and navigating the "Valley of Death" between discovery and clinical application. Leaders from the Leukemia and Lymphoma Society, Prostate Cancer Foundation, and the Alpha-1 Foundation detailed strategic investments that generated massive financial leverage and established critical infrastructure, such as patient registries and rapid autopsy programs, to overcome funding gaps and accelerate trial recruitment. The panel concluded that sustainable progress requires aligning academia, industry, and regulators while empowering patients to actively define research priorities and drive policy changes for faster approvals and reimbursement.
- Milken Institute1h 7m
Precision Medicine, Custom Cures
Margaret Anderson, Mike Polini, Jim Greenwood, George Church, Retta Berry, Chris Austin
Led by former NIH Director Francis Collins and moderated by Margaret Anderson, a diverse panel of scientists, industry leaders, and patient advocates examined the critical gap between rapid advances in precision medicine sequencing and clinical deployment. While the discussion highlighted success stories like the Berry family's transition from a diagnostic odyssey to effective treatment and the rising adoption of gene therapies, it also exposed systemic bottlenecks in rare disease therapeutics, reimbursement models, and data silos that prevent timely translation of genetic discoveries into cures. The group concluded that realizing the full potential of this medical revolution requires structural healthcare reform, robust data-sharing frameworks, and a shift toward participatory medicine where patients actively drive their own health outcomes.